[Federal Register Volume 78, Number 117 (Tuesday, June 18, 2013)]
[Notices]
[Pages 36594-36595]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-14456]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application GE 
Healthcare

    Pursuant to Title 21, Code of Federal Regulations 1301.34(a), this 
is notice that on April 29, 2013, GE Healthcare, 3350 North Ridge 
Avenue, Arlington Heights, Illinois 60004-1412, made application by 
renewal to the Drug Enforcement Administration (DEA) to be registered 
as an importer of Cocaine (9041), a basic class of controlled substance 
listed in schedule II.
    The company plans to import small quantities of ioflupane, in the 
form of three separate analogues of Cocaine, to validate production and 
quality control systems, for a reference standard, and for producing 
material for a future investigational new drug (IND) submission.
    Any bulk manufacturer who is presently, or is applying to be, 
registered with DEA to manufacture such basic class of controlled 
substance listed in schedules I and II, which falls under the authority 
of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in 
the circumstances set forth in 21 U.S.C. 958(i), file comments or 
objections to the issuance of the proposed registration and may, at the 
same time, file a written request for a hearing on such application 
pursuant to 21 CFR Sec.  1301.43, and in such form as prescribed by 21 
CFR Sec.  1316.47.
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than July 18, 2013.
    This procedure is to be conducted simultaneously with, and 
independent

[[Page 36595]]

of, the procedures described in 21 CFR Sec.  1301.34(b), (c), (d), (e), 
and (f). As noted in a previous notice published in the Federal 
Register on September 23, 1975, 40 FR 43745-46, all applicants for 
registration to import a basic classes of any controlled substances in 
schedules I or II are, and will continue to be, required to demonstrate 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, that the requirements for such 
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 
Sec.  1301.34(b), (c), (d), (e), and (f) are satisfied.

    Dated: June 7, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-14456 Filed 6-17-13; 8:45 am]
BILLING CODE 4410-09-P